Supplementary Table S4. Exposure to taselisib

Exposure to taselisib	*PIK3CA*-mutated (*n* = 20)	*PIK3CA*-MND (*n* = 27)	*PIK3CA* mutation status unknown (*n* = 13)	All patients (*N* = 60)
Median treatment duration, months (range)	4.7 (1.4−38.6)	3.9 (0.9−21.2)	5.3 (0.9−40.5)	4.6 (0.9−40.5)
Treatment duration, months, *n* (%)				
0–3	3 (15.0)	12 (44.4)	4 (30.8)	19 (31.7)
>3–6	10 (50.0)	5 (18.5)	4 (30.8)	19 (31.7)
>6–9	4 (20.0)	4 (14.8)	2 (15.4)	10 (16.7)
>9–12	0	3 (11.1)	1 (7.7)	4 (6.7)
>12	3 (15.0)	3 (11.1)	2 (15.4)	8 (13.3)
Median dose intensity, % (range)	90.5 (42−100)	99.4 (70−100)	81.3 (55−100)	97.1 (42−100)
Number of patients with dose reduction, *n* (%)	7 (35.0)	1 (3.7)	7 (53.8)	15 (25.0)

Treatment duration was defined as the number of months between the first and last treatment dates according to the dosing log. Dose intensity was defined as the actual dose received over the planned dose per the protocol. Dose reduction only took into account the dose given per day and did not consider dosing frequency.

MND, mutation not detected; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit-alpha.